Table 3.
List of publications evaluating the correlation between the expression levels of miR-21 and the outcome of patients with NSCLC
| Expression of miR-21 | Outcome of NSCLC patients | Sample size/type | Statistical method | References |
|---|---|---|---|---|
| ↑ | Shorter RFS (p = 0.042) and OS (p = 0.043) | 210 patients/tissue | Log-rank test | [96] |
| ↑ | Poor prognosis for OS (p = 0.011) | 423 patients (TCGA data) | Cox regression analysis | [101] |
| ↑ | Poor OS (p = 0.003) | 10 patients/plasma exosomes | Cox proportional hazard analysis | [95] |
| ↑ | Poor DFS (p = 0.016) | 195 patients/plasma exosomes | Log-rank test/multivariate Cox analysis | [106] |
| ↑ | Worse cancer-specific survival (p = 0.018/0.014) and RFS (p = 0.0005) | 317 patients/tissue | Univariate Cox analysis | [97] |
| ↑ | Reduced OS (p = 0.027) | 48 patients/tissue | Log-rank test | [74] |
| ↓ | Worse DSS (p = 0.027) | 95 lymph-node positive patients/tumor cells | Multivariate analysis | [105] |
| ↑ | Lower DFI (p = 0.022—tissue/p = 0.045—plasma) and OS (p = 0.037—tissue/p = 0.065—plasma) |
40 patients/tissue 37 patients/plasma |
Log-rank test | [107] |
| ↑ | Worse OS (p = 0.0045) | 261 patients (gefitinib treatment)/plasma | Univariate and multivariate analysis | [102] |
| ↑ | Shorter DFS (p = 0.008) | 58 patients/tissue | Cox proportional hazard regression model | [98] |
| ↑ | Poor OS (p = 0.015) | 88 patients/serum | Univariate and multivariate analysis | [103] |
| ↑ | Shorter OS and PFS (p < 0.001) | 204 patients/tissue | Multivariate logistic regression | [99] |
| ↑ |
Shorter OS (p = 0.0065—tissue) Poor prognosis (p = 0.019—serum) |
70 patients/serum and tissue |
Log-rank test Univariate cox analysis |
[108] |
| ↑ | Lower survival time (p = 0.001) | 80 patients/serum | Pearson correlation | [104] |
| ↑ | Lower PFS (p < 0.001) | 108 patients/plasma | Kaplan–Meier analysis | [109] |
| ↑ | Shorter DFS | 46 patients/tissue | Kaplan–Meier analysis | [78] |
| ↑ | Lower PFS (p = 0.0003) and OS (p = 0.0045) | 80 patients/tissue | Kaplan–Meier analysis | [100] |
NSCLC non-small cell lung cancer, RFS relapse/recurrence-free survival, OS overall survival, PFS progression-free survival, DFS disease-free survival, DSS disease-specific survival, DFI disease-free interval